Skip to content
University of Colorado Anschutz Medical Campus CU Anschutz
  • Webmail
  • UCD Access
  • Canvas
  • Quick Links
 

Tools & Resources

  • Events Calendar
  • Newsroom
  • Strauss Health Sciences Library
  • Department A-Z Directory
  • Campus Directory
  • Leadership
  • Faculty & Staff Resources
  • Supporter & Alumni Resources
  • Student Resources
  • Campus Map
  • University Policies
  • Give Now

CU Campuses

  • CU Anschutz Medical Campus
  • CU Boulder
  • CU Colorado Springs
  • CU Denver
  • CU System
  • CU Online

CU Anschutz Medical Campus

  • School of Dental Medicine
  • Graduate School
  • School of Medicine
  • College of Nursing
  • Skaggs School of Pharmacy and Pharmaceutical Sciences
  • Colorado School of Public Health

Barbara Davis Center for Childhood Diabetes

School of Medicine

  • Patient Care
    • Pediatric Clinic
    • Adult Clinic
    • Eye Clinic
    • Outreach and Telemedicine Clinics
  • Patient and Provider Resources
    • Clinical Care Resources
    • Publications
    • Patient Programs
  • Research
    • Basic and Translational Research Division
    • Diabetes Research Center
    • Clinical Research
    • Clinical Epidemiology
  • News & Events
    • BDC in the News
    • Conferences and Training
    • Events and Announcements
    • 3rd Childhood Diabetes Prevention Symposium - November 13th, 2020
    • 4th Childhood Diabetes Prevention Symposium - November 12th, 2021
    • 5th Childhood Diabetes Prevention Symposium - November 11th, 2022
  • Core Facilities
    • Autoantibody/HLA Core Facility
    • Cytometry Core Facility
    • Islet Core Facility
    • Molecular Biology Core Facility
  • Donate
  • About
    • Leadership
    • Faculty
    • Contact Us
    • Children's Diabetes Foundation
    • Rob Slover Memoriam
University Quick Links

Barbara Davis Center in the News

 


 

Dr. Satish Garg Speaks About Lower Insulin Prices on CBS News

Watch the CBS News Video Here

Smith Lab Hones in on B Cells’ Role in Diabetes

Full Story

Artificial Pancreas System Better Controls Blood Glucose Levels Than Current Technology

Full Story

One-Hour OGTT As Accurate As Two Hr OGTT For Diabetes Detection, Finds Study

Full Story

 2022 Joseph Addison Sewall Award recipient

 Lori AwardAs a researcher and program leader, Lori Sussel, PhD, has made extraordinary contributions to the University of Colorado that inspire, expand, and improve the work of her colleagues.

 Dr. Sussel is a professor of pediatrics and cell and developmental biology at the School of Medicine, director of basic and translational research at the Barbara Davis Center for Diabetes, and associate vice chancellor for basic science research on the Anschutz Medical Campus. She is also the inaugural recipient of the Sissel and Findlow Family Endowed Chair.

 Dr. Sussel was a member of the School of Medicine faculty from 1999 to 2007. An accomplished researcher of international renown, she was recruited to Columbia University, where her lab made important discoveries related to pancreatic development. She returned in 2016 to the CU School of Medicine, where she has served as an effective, visionary, and dynamic academic leader.

 Since Dr. Sussel’s return, she has continued to be a productive scientist, currently holding five National Institutes of Health Research Project Grants. Her scientific work focuses on the genetic instructions that set the course and drive pancreatic development.

 As a campus leader, Dr. Sussel built bridges between strong research programs so that the Anschutz Medical Campus in 2020 was once again recognized by the NIH as a Diabetes Research Center. By incorporating the breadth of diabetes research conducted on campus, the center is a model for collaboration and the foundation for a bold effort to create a Diabetes Across the Lifespan Initiative.

 At the beginning of the pandemic, Dr. Sussel stepped forward to serve as a COVID official and as a faculty advisor to campus leadership. She provided a collaborative, solutions-oriented approach that helped bring researchers back to their laboratories in a safe and productive environment.

 That role served as a proving ground for a new campus position: associate vice chancellor for basic science research. The position was created to ensure that the needs and interests of the basic science research community were represented and protected. Dr. Sussel has served in an exemplary fashion.

 Dr. Sussel has been instrumental in the creation and implementation of multi-institutional efforts that link programs in ways that strengthen all. In 2020, she helped start an initiative to promote research interactions between the Anschutz and Boulder campuses. She also has helped to develop a unified program on the Anschutz campus that offers central support for multi-investigator grants.

 A valued colleague, thoughtful designer of academic programs, and accomplished problem-solver, Dr. Sussel is an outstanding recipient of the Joseph Addison Sewall Award, which recognizes University of Colorado faculty members who make exceptional contributions of leadership and vision to the health sciences.

Congratulations, Dr. Sussel!


Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes

Author Contributions from the BDC's Gregory Forlenza, MD and Laurel Messer, PhD RN

Question:  Does once-daily oral verapamil preserve pancreatic beta cell function in children and adolescents with newly diagnosed type 1 diabetes?

Findings:  In a randomized clinical trial including 88 children and adolescents with newly diagnosed type 1 diabetes, C-peptide levels (a measure of pancreatic beta cell function) measured during a mixed-meal tolerance test 52 weeks after diagnosis were 30% higher with verapamil compared with placebo. The percentage of participants with a 52-week peak C-peptide level of 0.2 pmol/mL or greater was 95% in the verapamil group vs 71% in the placebo group. Verapamil had few adverse events.

Link to publication


Effect of Tight Glycemic Control on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes A Randomized Clinical Trial

Author Contributions from the BDC's Gregory Forlenza, MD and Laurel Messer, PhD RN

Question: Does near normalization of glucose levels preserve pancreatic beta cell function in youth with newly diagnosed type 1 diabetes?

Findings:  In a randomized clinical trial including 113 youths aged 7 to 17 years with newly diagnosed type 1 diabetes, there was no significant difference in C-peptide levels measured during a mixed-meal tolerance test (a measure of pancreatic beta cell function) 52 weeks after diagnosis between intensive management and standard care groups. Mean time in the target range of 70 to 180 mg/dL, measured with continuous glucose monitoring, at 52 weeks was 78% with intensive management, which included automated insulin delivery, compared with 64% with standard care.

Link to publication

“Use your blood glucose meter to help improve your health”

Our very own peds nurses Ashlee Ernst and Betsy Otten wrote this piece entitled “Use your blood glucose meter to help improve your health” published on Diatribe.org

https://diatribe.org/use-your-blood-glucose-meter-help-you-improve-your-health

T1GER study shows benefit of golimumab in newly diagnosed T1D: Box Title

Dr. Andrea Steck and her team participated in a phase II, multicenter, randomized, placebo-controlled trial examining the effects of golimumab, a TNF-α inhibitor, in pediatric type 1 diabetes (T1D). Children and young adults with newly diagnosed T1D had better endogenous insulin production and less exogenous insulin use after taking golimumab for 52 weeks, compared with those who took placebo. Mean 4-hour C-peptide area under the curve, as well as the number of those who had a partial-remission response, were higher in those who took golimumab, compared with those who took placebo.

https://www.nejm.org/doi/full/10.1056/NEJMoa2006136

FEATURED: Studies Find Better Glucose Control When Using Continuous Glucose Monitoring Devices

Continuous Glucose Monitors (CGM) are small devices that continually measure glucose levels under the skin, and transmit this information to a wireless device such as a receiver or cell phone. Two large multi-center studies recently published in the Journal of the American Medical Association (JAMA) tested if these devices improved glycemic control or reduced incidence of life-threatening low glucose levels in two very unique populations: adolescents and older adults living with type 1 diabetes. The CITY (CGM Intervention in Teens and Young Adults with type 1 diabetes) trial was a six month randomized controlled trial that showed that CGM helps adolescents and young adults manage their type 1 diabetes more effectively, compared with daily use of blood glucose finger-stick testing. The CGM users saw significant reductions in their hemoglobin A1C levels and less time spent with severe high and low blood glucose levels. Barbara Davis Center clinical and research staffs, including investigators Laurel Messer, PhD, Viral Shah, MD and Paul Wadwa, MD, were involved in the conduct of both landmark clinical trials.

Links to the two press releases are found here:

Release 1 - "Study Finds Better Glucose Control for Young People Using Continuous Monitoring Devices"

Release 2 - "Continuing Glucose Monitoring Reduces Hypoglycemia in Older Adults With Type 1 Diabetes"

Links to the two articles are found here:

https://jamanetwork.com/journals/jama/article-abstract/2767160

https://jamanetwork.com/journals/jama/article-abstract/2767159

9NEWS Q&A: Can the coronavirus trigger type 1 diabetes in kids?

The Barbara Davis Center for Diabetes saw a 40% increase in Type 1 Diabetes during the pandemic.

Diabetes treatment centers saw a surge in type 1 diabetes patients that may correlate with the coronavirus pandemic.That's according to Dr. Brigitte Frohnert, associate professor at the Barbara Davis Center for Childhood Diabetes at University of Colorado-Anshutz. 

9NEWS sat down with Frohnert to discuss causes for type 1 diabetes, an autoimmune disorder, and how the coronavirus may play a role in triggering it.

Link to Full Interview  Author: Katie Eastman

 

Artificial pancreas effectively controls type 1 diabetes in children age 6 and up

The artificial pancreas is an “all-in-one” diabetes management system that tracks blood glucose levels using a continuous glucose monitor and automatically delivers insulin when needed

A clinical trial at the Barbara Davis Center for Childhood Diabetes at the University of Colorado Anschutz Medical Center and three other pediatric diabetes centers in the United States has found that a new artificial pancreas system — which automatically monitors and regulates blood glucose levels — is safe and effective at managing blood glucose levels in children as young as age six with type 1 diabetes. The trial was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health. Results from the trial were published August 26 in the New England Journal of Medicine.

FEATURED: An Ultradian Notch in Beta-Cell Development, Utpal B. Pajvani, M.D., Ph.D., and Lori Sussel, Ph.D.

Published in the New England Journal of Medicine 383(1):80-82 · July 2020

A study of genetically manipulated mouse models has shown that ultradian cycles of expression of a particular protein influence specification of cell type in the pancreas, a finding that has implications for understanding beta-cell identity and function.

Link to full article in the New England Journal of Medicine


laurel clinical epi

Dr. Laurel Messer discusses greater engagement with diabetes care linked to lower glucose levels for young people

Full Story >>

marian-rewers_300

 

Dr. Marian Rewers' research suggests SARS-CoV-2 Infection Not Associated with Autoimmunity Related to T1D Development

 Full Story >>

Dr. Andrea Gerard Gonzalez discusses how for diabetes patients, new health threats and cost concerns surface during coronavirus.

Full Story >>

Uchenna 2

NFL player, Uchenna Nwosu visits the Barbara Davis Center and plays football with kids

Full Story >>

 

Dr. Aaron Michels' Research using Methyldopa for Prevention of T1D.

Full Story>>

 ultra-sound-diabetes-4

Dr. Richard Benninger and Richard Ramirez use ultrasound technology to track T1D

Full Story>>

SatishGarg-web-optimized_300

Dr. Satish Garg talks about first-ever oral drug for T1D

Full Story>>

TEDDY_IMAGE

Participating in T1D Trials, The Value of Knowing 

Full Story>>

  
ASK

"Just ASK to Know:" One family's journey before and after screening for T1D

Full Story>>

 

 

Events

Conferences and Training

CU School of Medicine Media Relations

Mark Couch - Director of Communications, Chief of Staff

Phone: 303.724-5377

  • Contact Us
  • Website Feedback
  • CU System
  • Privacy Policy
  • Terms of Use
  • Accessibility
  • Accreditation
  • Employment
  • Give Now
 

© 2023 The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.

CMS Login

Webmail

UCD Access

Canvas

Opens in a new window Opens document in a new window